Podcasts about adces

Jasmine Gonzalvo, PharmD, MPH, CDCES, FADCES, joins this episode to discuss the importance of curiosity, effective communication and cultural sensitivity in diabetes care. She shares her personal approach to exploring barriers to insulin in clients and highlights how motivational interviewing can be a powerful tool in navigating treatment conversations—especially when addressing common misconceptions about insulin. The conversation emphasizes the importance of open-ended questions, recognizing personal biases, and creating safe spaces for honest dialogue. By nurturing relationships and meeting patients where they are, diabetes care and education specialists can better support lasting behavior change and improve health outcomes.This episode is sponsored by Lilly. ResourcesA link to the insulin myths tip sheet mentioned in this episode is coming soon. ReferencesNahid Dehghan-Nayeri, Fatemeh Ghaffari, Tahereh Sadeghi, Naser Mozaffari; Effects of Motivational Interviewing on Adherence to Treatment Regimens Among Patients With Type 1 Diabetes: A Systematic Review. Diabetes Spectr 1 May 2019; 32 (2): 112–117.Guy E H M Rutten, Heidi Van Vugt, Eelco de Koning - Person-centered diabetes care and patient activation in people with type 2 diabetes: BMJ Open Diabetes Research & Care 2020;8:e001926.Entwistle VA, Carter SM, Cribb A, McCaffery K. Supporting patient autonomy: the importance of clinician-patient relationships. J Gen Intern Med. 2010 Jul;25(7):741-5. doi: 10.1007/s11606-010-1292-2. Epub 2010 Mar 6. PMID: 20213206; PMCID: PMC2881979. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Becky Sulik, RDN, LD, CDCES, and Bethany Long, BSN, RN, CDCES, join us to discuss how automated insulin delivery systems (AID), like the Omnipod 5, are transforming diabetes management and making mealtime bolusing easier. Becky and Bethany share insights on the Omnipod 5 AID system, including user-friendly built-in features that facilitate onboarding and increase carb awareness skills in a variety of people with diabetes. The episode highlights real-world applications and personal stories that diabetes care and education specialists can utilize in practice to quickly onboard and empower their clients today.  This episode was supported by Insulet. A guest featured on this show has a commercial relationship with Insulet, and another guest is an employee of the company. The opinions expressed in this webinar are those of the speakers and do not reflect the views or positions of Insulet.Resources: Omnipod resources for healthcare professionals: www.omnipod.com/hcp  Omnipod 5 Custom Foods blog post: www.omnipod.com/hcp/blog/tips-guidelines/custom-foods  Omnipod 5 Custom Foods brochure: www.omnipod.com/sites/default/files/omnipod-5_hcp_custom-foods-guide_us-english.pdf  Omnipod 5 simulator app for iOS: apps.apple.com/us/app/omnipod-5-simulator/id1552469689  Omnipod 5 simulator app on Google Play: play.google.com/store/apps/details?id=com.insulet.simulator&hl=en_US&gl=US&pli=1  References: Davis GM, et al. Simplified Meal Bolus Strategies for the Omnipod®5 Automated Insulin Delivery (AID) System in People with Type 2 Diabetes (T2D): Sub-Analysis of the SECURE-T2D Study. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Post-hoc analysis limits conclusions. Insulet Data on file. RF-062025-00012Important safety information: The Omnipod® 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin and type 2 diabetes in persons aged 18 and older. Rx only.  WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Today on Update, I am talking with Jodi Lavin-Tompkins, Diabetes Care and Education Specialist with adces.org. That stands for Association of Diabetes Care and Education Specialists. Jodi will define diabetes and how it affects your body. She will talk about risk factors and what you can do to lower your glucose levels. Finally, we will discuss how diabetics need to be extra careful in excessive heat by drinking extra water.

On this episode of the Huddle, Kelly Postiglione Cook, RN, MSN, ANP-BC, CDCES, BC-ADM, and Sean Oser, MD, MPH, CDCES have a conversation about the importance of utilizing automated insulin delivery systems, like the iLet bionic pancreas, more widely in primary care. They provide insight into a study that evaluated the success of implementing use of the iLet bionic pancreas in a primary care setting, how the results illustrated that this technology can be more widely utilized in these settings, and the role diabetes care and education specialists can play in this work.This episode is sponsored by Beta Bionics. Episode References: Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med 2022;387:1161-1172 DOI: 10.1056/NEJMoa2205225 Russell SJ, Selagamsetty R, Damiano E. Real-world efficacy of the iLet bionic pancreas in adults and children during the first eighteen months of commercial availability. Presented at the American Diabetes Association 85th Scientific Sessions, June 20-23, 2025, Chicago, IL.   Oser SM, Putman MS, Russel SJ, et al. Assessing the iLet Bionic Pancreas deployed in primary care and via telehealth: a randomized clinical trial. Clin Diabetes 2025; cd240104. https://doi.org/10.2337/cd24-0104 Oser C, Parascando JA, Kostiuk M, et al. Experiences of people with type 1 diabetes using the iLet bionic pancreas in primary care: A qualitative analysis. Clin Diabetes 2024 https://doi.org/10.2337/cd24-0060.  Sulik B, Postiglione Cook K, MacLeod J. Meals no longer need to be math problems: Shifting from precise carbohydrate counting to a continuum of carbohydrate awareness as automated insulin delivery advances. Diabetes Technology and Obesity Medicine 2025;1(1):79-83. DOI: 10.1089/dtom.2025.0010.  Resources:Learn more about Beta Bionics here: https://www.betabionics.com/Explore the latest in diabetes technology on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about a two-part course on integrating diabetes technology into primary care, put on through the collaboration of AANP and ADCES:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical ScenariosPart 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case StudiesDive deeper into how diabetes technology can be incorporated into primary care on another recent episode of The Huddle featuring Kathryn Evans Kreider DNP, FNP-BC, BC-ADM, FAANP: https://thehuddle.simplecast.com/episodes/embracing-diabetes-technology-in-primary-care Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

On the latest episode of The Huddle, we're joined by Jay Shubrook, DO, BC-ADM, FACOFP, FAAFP, Anne Lee, MEd, RDN, CDCES, and Clipper Young, PharmD, MPH, as they talk about Touro University' unique Mobile Diabetes Education Center (MOBEC). They explain how the center was formed, the services MOBEC provides, and how others can replicate this work to serve and educate a greater population of people with and at risk for diabetes.Learn more about MOBEC here: Touro University Californiahttps://diabetesjournals.org/clinical/article/42/1/125/153645/Community-Based-Diabetes-Awareness-Strategy-With  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

On this episode of The Huddle, Wendy Mobley-Bukstein, PharmD, BCACP, CDCES, CHWC, NASM-CPT, FAPhA, FADCES and Debbie Hinnen, APN, BC-ADM, CDCES, FAAN discuss the importance of medication persistence, how to talk to clients about starting and staying on diabetes medications, and strategies to help clients stay consistent with their medication taking. This episode was made possible with support from Lilly, A Medicine Company.Learn more about the latest in diabetes technology on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about the ADCES7 Self-Care Behaviors: Self-Care Tips (ADCES7)References:Kennedy-Martin, T., Boye, K. S., & Peng, X. (2017). Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Preference and Adherence, 11, 1103–1117. https://doi.org/10.2147/PPA.S136639McGovern, A., Hinton, W., Calderara, S. et al. A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther 9, 229–242 (2018). https://doi.org/10.1007/s13300-017-0361-5Evans M, Engberg S, Faurby M, Fernandes JDDR, Hudson P, Polonsky W. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes Obes Metab. 2022; 24(3): 377-390. doi:10.1111/dom.14603Sabaté E., Adherence to Long-Term Therapies: Evidence for Action, 2003, World Health Organization, Geneva, Switzerland.https://www.ama-assn.org/delivering-care/physician-patient-relationship/8-reasons-patients-dont-take-their-medicationshttps://www.npr.org/sections/health-shots/2017/09/08/549414152/why-do-people-stop-taking-their-meds-cost-is-just-one-reasonhttps://www.adces.org/docs/default-source/handouts/adces7/handout_pwd_adces7_takingmedication.pdf?sfvrsn=4e3f6359_13 Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

This week on The Huddle, we're resharing an episode from last summer featuring Kristine Batty, PHD, APRN, BC-ADM, CDCES, FADCES as she discusses her experience both living with Type 1 diabetes and working with people with diabetes as a certified diabetes care and education specialist. She shares the importance of putting yourself in your client's shoes in order to understand their goals and pain points and support their needs, especially when it comes to diabetes technology.Visit danatech here: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about the latest developments in T1D screening here: T1D ScreeningView Kristine's video series below:https://www.youtube.com/watch?v=HPqraDx-aQwhttps://www.youtube.com/watch?v=SBYpv3LuzBwhttps://www.youtube.com/watch?v=otRUIrx6FkIhttps://www.youtube.com/watch?v=uDrDSSK99-A Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Registration is open now for ADCES25 taking place August 8-11 in Phoenix, AZ! Our conference planning chair Christina Whitehouse, RN, MSN, APRN, ARNP, FADCES, CDCES, shares what to look forward to at this year's conference, and why ADCES' annual conference is the place to be for all diabetes care and education specialists and other professionals in the diabetes space. Register for this year's annual conference at ADCES 2025 Annual MeetingExplore all there is to see in Phoenix at Roosevelt Row Arts District | Downtown Phoenix Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

On this episode of The Huddle, Chris Memering, MSN, RN, CDCES, BC-ADM, talks about the value that diabetes care and education specialists bring to the inpatient care setting. She outlines the importance of continuity of care between the inpatient and outpatient setting, how DCES in inpatient help increase patient satisfaction and safety, and how others in the inpatient setting can demonstrate their value to their hospital leadership.Learn more about how to showcase the value of the diabetes care and education specialty in our value toolkit created especially for ADCES members. Log in here to view the toolkit:  Showcase Value ToolkitOr click here to become an ADCES member to access helpful resources like this one: MembershipLearn more about ADCES' inpatient certificate program focused on knowledge and skills necessary for effective inpatient diabetes care: https://www.adces.org/store/certificate-programs/detail/inpatient-certificate-program-transforming-care-and-enhancing-lives Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

This week on The Huddle, we're resharing a discussion with current ADCES President, Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes.  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

In the first episode in a multi-part diabetes technology series, Kathryn Evans Kreider DNP, FNP-BC, BC-ADM, FAANP, joins The Huddle to discuss integrating diabetes technology into primary care. She talks about the importance of embracing digital technology in primary care and how health care professionals in primary care can take tangible steps to better utilize the technology available to them.Learn about the latest advances in diabetes technology on danatech:  Diabetes technology for healthcare professionals | DanatechCheck out the two-part Integrating Diabetes Technology into Primary Care course here: Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical ScenariosPart 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies   Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Michael See MS, ACSM-CEP, NBCHWC, CDES joins the Huddle to share his expertise and experiences in bringing physical activity to people with type 2 diabetes who also have physical limitations. He covers topics like how to assess physical limitations, their prevalence in people with type 2 diabetes, and how to use a motivational interviewing approach in conversations with your clients. This episode was made possible with support from Lilly, A Medicine Company. Learn more about this topic in our latest patient/client handout (support for the development of this handout was provided by Lilly, A Medicine Company): adces_tipsheet_physical_activity2.pdf ReferencesAmerican Diabetes Association Professional Practice Committee; 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S77–S110.Ahmad E, Sargeant JA, Yates T, Webb DR, Davies MJ. Type 2 Diabetes and Impaired Physical Function: A Growing Problem. Diabetology. 2022; 3(1):30-45. https://doi.org/10.3390/diabetology3010003Angulo, J., Assar, M. E., Álvarez-Bustos, A., & Rodríguez-Mañas, L. (2020). Physical activity and exercise: Strategies to manage frailty. Redox Biology, 35. https://doi.org/10.1016/j.redox.2020.101513Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079. doi:10.2337/dc16-1728O'Neill D, Forman DE. The importance of physical function as a clinical outcome: Assessment and enhancement. Clin Cardiol. 2020;43(2):108-117. doi:10.1002/clc.23311Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25 Suppl 3:1-72. doi:10.1111/sms.1258136-Item Short form survey instrument (SF-36). Available at: https://www.rand.org/content/dam/rand/www/external/health/surveys_tools/mos/mos_core_36item_survey.pdf (Accessed: 21 October 2024). Physical activity vital sign. Available at: https://www.exerciseismedicine.org/wp-content/uploads/2021/04/EIM-Physical-Activity-Vital-Sign.pdf (Accessed: 21 October 2024).  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Eileen Egan, DNP, FNP-C, BC-ADM, CDCES, FADCES joins The Huddle to share her expertise about the interplay between weight and glycemic management in people with Type 2 diabetes, the importance of meeting glycemic and weight goals early after a Type 2 diabetes diagnosis, as well as best practices for helping people stay motivated and engaged. This episode was made possible with support from Lilly, A Medicine Company. Learn more about this topic in this accompanying patient/client handout (support for the development of this handout was provided by Lilly, A Medicine Company): adces_tipsheet_early_control2.pdf References:American Diabetes Association. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes- 2024. Diabetes Care, 47(1): S145-S157.Center for Disease Control and Prevention. Adult overweight and obesity. https://www.cdc.gov/obesity/basics/adult-defining.htmlDCCT/EDIC study research group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39(5):686-693. Gregg E, Jakicic J, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol. 2016; 4(11): 913-921.Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci. 2021. 27;22(21):11629.Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2003;32(4):855-867. Jin X, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-2424.  Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.Lancet Diabetes Endocrinol. 2019;7(5):344-355.Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022 Jan 22;399(10322):394-405. doi: 10.1016/S0140-6736(21)01919-X. Epub 2021 Sep 30. Erratum in: Lancet. 2022 Jan 22;399(10322):358. PMID: 34600604Rachel G. Miller, Trevor J. Orchard; Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 1 March 2020; 69 (3): 291–299. https://doi.org/10.2337/db19-0514Ross, R., Neeland, I.J., Yamashita, S. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol16, 177–189 (2020). https://doi.org/10.1038/s41574-019-0310-7Thom G, McIntosh A, Messow CM, et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes Obes Metab. 2021;(23):711-719.Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):ITC33-ITC48.Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.World Health Organization. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1 Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

On our latest episode of The Huddle, Sheetal Shah, founder of MettaHealth Partners discusses the evolving realm of AI, the role DCESs and other health care professionals can play in embracing and adopting AI technology, and the importance of keeping a human element in the technology.Learn more about MettaHealth Partners here: MettaHealth PartnersLearn more about the National Institute of Standards and Technology (NIST) here: National Institute of Standards and TechnologyStay up to date on all things related to diabetes technology on danatech: Diabetes technology for healthcare professionals | Danatech Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

During a special episode of The Huddle recorded live at our 2024 annual meeting, we sat down with incoming ADCES President Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the impact she wants to leave behind as President this coming year, as well as the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes. Please note: since the recording of this episode, Kirsten Yehl has since moved on from ADCES to pursue another professional opportunity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Lucia Novak MSN, ANP-BC, BC-ADM joined The Huddle to discuss the role of basal insulin in type 2 diabetes, when to initiate it, and how to have discussions about basal insulin with your clients that make them feel comfortable, informed and empowered.This episode was made possible with support from Lilly, A Medicine Company.Resources: American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S158–S178. https://doi.org/10.2337/dc24-S009Look AHEAD (Action for Health in Diabetes) study. Look AHEAD (Action for Health in Diabetes)Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41(7): e113-e114.Find a DSMES program near you here: Find an Accredited Diabetes Education Program Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

People with diabetes who are newly starting insulin may have concerns and fears, many of which are caused by beliefs about insulin that may not be accurate. Susan Guzman, PhD, joined The Huddle to talk about the potential fears that may come up when someone is starting insulin, and how diabetes care and education specialists can address these fears and provide support so that people feel comfortable and informed when taking insulin.   This episode was made possible with support from Lilly, A Medicine Company. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Having elevated cortisol levels can lead to a variety of side effects, and it may impact people with diabetes in a number of ways. Natalie J. Bellini DNP, FNP-BC, BC-ADM, CDCES joined The Huddle to talk about hypercortisolism, how it is diagnosed, and its potential effects on type 2 diabetes management. This episode is sponsored by Corcept.Learn more about Corcept here: Corcept TherapeuticsView a recorded webinar that dives deeper into cortisol levels and diabetes management (sponsored by Corcept): A Closer Look at Difficult-to-Manage Diabetes – Is Cortisol at Play?Learn more about the CATALYST study: Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions – Corcept Therapeutics, Incorporated Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Diabetes-related foot conditions like ulcers and amputations can be very serious, but these complications are preventable when comprehensive foot exams are prioritized. Podiatrist Dr. Mark Hinkes joined The Huddle to talk about the importance of foot health and comprehensive foot exams for people with diabetes, and how we can use data collected from these foot exams to predict potential future risk. Learn more about the International Working Group on the Diabetic Foot here: Home - IWGDF GuidelinesView Mark's book "Healthy Feet for People with Diabetes" here: Healthy Feet for People With Diabetes: Hinkes DPM, Dr. Mark: 9780985628604: Books - Amazon.caLearn more about diabetes-related foot complications:Foot Complications | ADAFive year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer | Journal of Foot and Ankle Research | Full Text Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

On this episode of The Huddle, we're joined by Lucille Hughes, DNP, MSN/Ed, CDCES, BC-ADM, FADCES, Director of Scientific Communication, Information, and Education at Embecta. Lucille discusses some of the unique care needs to consider when working with people with Type 2 diabetes who take insulin, how the DCES and other members of the diabetes care team can help to address their specific diabetes burdens and struggles, and how care for people with Type 2 diabetes differs from that of Type 1 diabetes.This episode is sponsored by Embecta.Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)Learn more about Embecta here: Discover Our Diabetes Care Products & Learn About EMBECTA Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Recorded live at ADCES24, we sat down with Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, CDTC, FADCES​ to talk about the latest in diabetes technology and what to expect in the coming year, how diabetes technology overall is evolving and changing, and how diabetes technology can more seamlessly be integrated into primary care settings.Please note that this episode was recorded in August and some of the technology and updates discussed in future tense may now be in different stages of development or release. References to specific devices and manufacturers are for educational purposes and do not represent an endorsement from ADCES.Links: Register to view ADCES24 on-demand content: ADCES24 (adcesmeeting.org)Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)Find your technology competency level and resources to dive deeper with our tech competency tool: Technology Competency Finder| Danatech (adces.org)To learn more about the latest and greatest in diabetes technology, register for our Diabetes Technology Conference: Diabetes Technology Conference 2024 (eventscribe.net)To take a deeper dive into the integration of diabetes technology in primary care by checking out this two-part course developed in partnership with the American Association of Nurse Practitioners (Made possible thanks to a grant from Helmsley Charitable Trust).:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical Scenarios (0.75 CE/CME)Part 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies (1 CE/CME)Learn more about the PANTHER Program: Diabetes Technology. Deciphered. | PANTHER ProgramVisit diatribe: Making Sense of Diabetes | DiaTribeVisit the Medical Professional's Reference website: Prescription & OTC Drug Info | Side Effects, Interactions & Dosages (empr.com)Visit the ADA Consumer Guide: ADA Consumer Guide (diabetes.org)Find resources from DiabetesWise: Home » DiabetesWise Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Send us a textLisa La Nasa is a mom of two, wife, adventurer, coffee fanatic, and founder and CEO of diaVerge Diabetes. Lisa founded diaVerge Diabetes in 2015 after her own personal discovery of the empowerment and complete lifestyle transformation that can come from gaining better control of type 1 diabetes. Lisa has successfully been maintaining A1c levels

Recorded live at the ADCES24 annual meeting, we sat down with Senior Manager of the Diabetes Education Program at HealthPartners, Erin L. DaRosa, MBA, RDN, LD, CDCES. Erin discussed how she showcases the value of the DCES specialty in her own work and how you can speak the language of key stakeholders in your practice to articulate your value, as well as how to build trust and get a seat at the table.Learn more about HealthPartners here: HealthPartners – Top-Rated insurance and health care in Minnesota and WisconsinRegister to view ADCES24 on-demand sessions here: ADCES24 (adcesmeeting.org) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

This week on The Huddle, we're resharing an episode with Miguel Johns, Co-Founder & CEO of mmnt and creator of Milton. Miguel discussed how the use of artificial intelligence (AI) can benefit health care professionals across the diabetes space and how this technology is growing and changing. Topics include addressing some of the current opportunities and challenges associated with AI in health care, how AI can provide improved clinical decision support, and where this technology may be headed in the future.Explore danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org)For more information on Miguel or mmnt, visit Milton | Powered by MMNT (getmilton.com)View a recorded annual conference session on AI and more by registering for ADCES24 On Demand: ADCES24: Diabetes Care, Education and Technology (mcievents.com)Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

This episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, our second related to the Association of Diabetes Care and Education Specialists (ADCES) 2024 annual meeting, spotlights new data and perspectives from the meeting brought forth by pharmaceutical and diabetes technology companies. Check out our first episode related to ADCES 2024. A large theme of the episode is discussion around data and interactions with Lexicon, which announced the resubmission of a New Drug Application for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control among adults with type 1 diabetes and chronic kidney disease. According to the FDA, the agency considers the resubmission a complete response to its 2019 letter regarding sotagliflozin for type 1 diabetes.1 For this application, the FDA has assigned a Prescription Drug User Fee Act review date of December 20, 2024. On August 21, 2024, Lexicon Pharmaceuticals announced the FDA's intention to host an advisory board meeting regarding this application.2 Of note, sotagliflozin (Inpefa) has received approval in heart failure for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors in May 2023.3 Following this, the conversation between hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, shifts to a discussion on Medtronic's collaboration with Abbott, with the hosts praising this partnership as a strategic move to improve sensor technology for patients. The episode then highlights the innovative educational approach to learning about the Sequel Twiist, with Sequel hosting a jeopardy-style game to engage attendees in learning about their upcoming pump product. Finally, the hosts explore the Diabetotech certificate program, which offers in-depth education on various diabetes technologies, and emphasize the importance of continuous learning and unbiased educational resources in the rapidly evolving field of diabetes management. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

The Association of Diabetes Care and Education Specialists (ADCES) is an organization ahead of its time in the world of healthcare. Often, those in medicine find the field to be reactionary instead of proactive in addressing the rising burden of chronic disease. The ADCES, formerly the American Association of Diabetes Educators, was founded in 1973 to support and educate clinicians, care providers, and patients of the latest advancements to improve care and quality of life for people with diabetes. This mission, while important in the 1970s, has become crucial if health systems hope to combat a burgeoning diabetes crisis. In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, we celebrate the ADCES 2024 annual meeting through the perspective of hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center. The first of 2 scheduled episodes related to the meeting, this episode focuses on presentations and sessions Isaacs and Bellini were directly involved in from the meeting. Key topics include the challenges of using insulin pumps for type 2 diabetes, the role of DME companies in accessing CGM for people with Medicare, and the latest research on automated insulin delivery systems during pregnancy. The hosts also discuss interpreting ambulatory glucose profiles and time-in-range targets. Throughout the conversation, Isaacs and Bellini share their enthusiasm for the advancements in diabetes technology and the importance of effective patient education and counseling. Video Version: https://www.hcplive.com/view/diabetes-dialogue-navigating-adces-2024 

For those with diabetes who use insulin pump therapy, having access to training and education on this technology is key to success. David Jopke, DNP, FNP-C, BC-ADM, CDCES, Tracy Newell RD LD, CDCES, RD, LD, CDCES, Erin L. DaRosa, MBA, RDN, LD, CDCES join The Huddle to talk about their experiences creating a  team-based formal process for becoming an insulin pump trainer, and how practice settings that want to offer insulin pumps and automated insulin delivery system options to people with diabetes can create their own formalized process.Learn more about HealthPartners here: HealthPartners – Top-Rated insurance and health care in Minnesota and WisconsinView danatech's resources on insulin pumps & AID here: Insulin Pumps l diabetes training and education l Danatech (adces.org)Learn more about the Panther program here: Diabetes Technology. Deciphered. | PANTHER Program Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

We know research is crucial for making continued advances in diabetes care for all populations. Rachel Stahl-Salzman, MS, RD, CDN, CDCES, and Kerri Knippen, PhD, RDN, LD, BC-ADM, FAND, join us on The Huddle to talk about their latest research projects related to pregnancy in diabetes, some of the outcomes and learnings of each study, and how diabetes care and education specialists can be leaders in this work, even without a research background.View Rachel's research poster diving deeper into this topic here: Annual QIPS Symposium | Weill Department of Medicine (cornell.edu)Learn more about Kerri's project here: https://www.eeds.com/enduring_material.aspx?AIN=005243415&SIN=230144&Display_Portal_Nav=true https://bsmh.zoom.us/rec/play/dNYY9PJAVNjh_wJCglFQuYOU9GYRTC4JYP1xEr3eqd5037qGu1kvWbgs0Mw35SdAhBtm-W66tyZCnDv8.FBeiYIeEMAKXck4F?canPlayFromShare=true&from=share_recording_detail&startTime=1713455116000&componentName=rec-play&originRequestUrl=https%3A%2F%2Fbsmh.zoom.us%2Frec%2Fshare%2F6jgesPiUBq5EIbX8P7K0pzRJ4yKEb-HPxmBMMhqUZxbBBqREek8OvlNR7vh3aQR2.hQwbtfqHOQ8tp3uF%3FstartTime%3D1713455116000Join the poster presentations at #ADCES24 to learn even more about Kerri and Rachel's work! Learn more and register for the conference here: ADCES24 (adcesmeeting.org)Learn more about the ADCES Foundation here: ADCES Foundation Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Kristine Batty, APN, BC-ADM, and CDCES talks about her experience both living with Type 1 diabetes and working with people with diabetes as a CDCES, and how understanding both sides of the desk can help to optimize health outcomes. Visit danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org) View Kristine's video series below:Reducing Diabetes Technology Burnout (youtube.com)Continuous Glucose Monitoring: Managing Expectations (youtube.com)Breaking Down Diabetes Technology Barriers (youtube.com)The Essentials of CGM Accuracy (youtube.com) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

This episode is sponsored by Medtronic.Painful diabetic peripheral neuropathy (DPN) can significantly impact a person with diabetes and their quality of life. Nalani Hunsaker PA-C, MCMSc, BC-ADM, a paid consultant for Medtronic, joins The Huddle to talk about Medtronic's spinal cord stimulation therapy option, how the procedure works, and its success in relieving pain from DPN. Please reach out to http://www.medtronic.com/dpnconnect to connect with a Medtronic representative today. If you would like to share more information with your patients check out http://www.medtronic.com/dpnpain References:1. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: A multicentre randomized clinical trial. Pain. 2014;155(11):2426–2431. doi:10.1016/j.pain.2014.08.031 2. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: A prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684 3. Medtronic Pain Therapy Clinical Summary M221494A016 Rev B. United States; 2022. 4. van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32–38. doi:10.2337/dc17-0983 5. Zuidema X et al. Long-term Evaluation of Spinal Cord Stimulation in Patients With Painful Diabetic Polyneuropathy: An Eight-to-Ten-Year Prospective Cohort Study. Neuromodulation. 2022 Dec 30:S1094-7159(22)01403-9. 6. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019;380(20):1895-19057. Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine (Phila Pa 1976). 2015 1;40(9):E531-7.8. Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8 https://creativecommons.org/licenses/by/4.0/.9. Temel Y, Ackermans L, Celik H, et al. Management of hardware infections following deep brain stimulation. Acta Neurochir (Wien). April 2004;146(4):355-361.10. Pepper J. Zrinzo L, Mirza B, Foltynie T, Limousin P, Hariz M. The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. Stereotact Funct Neurosurg. 2013;91(1):56-65.11. Tolleson C, Stroh J, Ehrenfeld J, Neimat J, Konrad P, Phibbs F. The factors involved in deep brain stimulation infection: a large case series. Stereotact Funct Neurosurg. 2014;92(4): 227-233.12. Thrane JF, Sunde NA, Bergholt B, Rosendal F. Increasing infection rate in multiple implanted pulse generator changes in movement disorder patients treated with deep brain stimulation. Stereotact Funct Neurosurg. 2014;92(6):360-364.13. Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management [published correction appears in Neuromodulation. July 2017;20(5):516]. Neuromodulation. January 2017;20(1):31-50.14. Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, Cheng J. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. March-April 2011;11(2):148-153.15. Falowski SM, Provenzano DA, XIa Y, Doth AH. Spinal Cord Stimulation Infection Rate and Risk Factors: Results From a United States Payer Database. Neuromodulation. February 2019;22(2):179-189.16. Clifton M, Quirouet A, Pizarro-Berdichevsky J, et al. Infection rate after sacral neuromodulation surgery: a review of 1033 InterStim procedures. J Urol. April 2016;195(4S):851.17. Bjerknes S, Skogseid IM, Sæhle T, Dietrichs E, Toft M. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PLoS One. August 14, 2014;9(8):e105288.18. Piacentino M, Pilleri M, Luigi Bartolomei L. Hardware-related infections after deep brain stimulation surgery: review of incidence, severity and management in 212 single-center procedures in the first year after implantation. Acta Neurochir (Wien). December 2011; 153(12):2337-2341.19. Hamani C, Lozano AM. Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84(5-6):248-251.20. Hayek SM, Veizi E, Hanes M. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center Database. Neuromodulation. October 2015;18(7):603-608. 21. Bendel MA, O'Brien T, Hoelzer BC, et al. Spinal Cord Stimulator Related Infections: Findings From a Multicenter Retrospective Analysis of 2737 Implants. Neuromodulation. August 2017;20(6):553-557. 22. Wexner SD, Hull T, Edden Y, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. J Gastrointest Surg. July 2010;14(7):1081-1089.15 23. Chen T, Mirzadeh Z, Lambert M, et al. Cost of Deep Brain Stimulation Infection Resulting in Explantation. Stereotact Funct Neurosurg. 2017;95(2):117-124.24. Provenzano DA, Falowski SM, Xia Y, Doth AH. Spinal Cord Stimulation Infection Rate and Incremental Annual Expenditures: Results From a United States Payer Database. Neuromodulation. April 2019;22(3):302-310.25. Medtronic data on file: Economic Impact of Infection Related to Neuro-Stimulator Implant. Study report prepared for Medtronic prepared by Optum, 2018/01/03.26. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-2735. 27. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. May 16, 2019;380(20):1895-190528. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-273529. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. April 2021. doi:10.1001/jamaneurol.2021.0538 Spinal Cord Stimulation Brief Summary INDICATIONS Spinal cord stimulation (SCS) is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. CONTRAINDICATIONS Diathermy - Energy from diathermy can be transferred through the implanted system and cause tissue damage resulting in severe injury or death. WARNINGS Sources of electromagnetic interference (e.g., defibrillation, electrocautery, MRI, RF ablation, and therapeutic ultrasound) can interact with the system, resulting in unexpected changes in stimulation, serious patient injury or death. An implanted cardiac device (e.g., pacemaker, defibrillator) may damage a neurostimulator, and electrical pulses from the neurostimulator may cause inappropriate response of the cardiac device. Patients with diabetes may have more frequent and severe complications with surgery. A preoperative assessment is advised for some patients with diabetes to confirm they are appropriate candidates for surgery. PRECAUTIONS Safety and effectiveness has not been established for pediatric use, pregnancy, unborn fetus, or delivery. Avoid activities that put stress on the implanted neurostimulation system components. Recharging a rechargeable neurostimulator may result in skin irritation or redness near the implant site. ADVERSE EVENTS May include: undesirable change in stimulation (uncomfortable, jolting or shocking); hematoma, epidural hemorrhage, paralysis, seroma, infection, erosion, device malfunction or migration, pain at implant site, loss of pain relief, and other surgical risks. Adverse events may result in fluctuations in blood glucose in patients with diabetes. Refer to www. medtronic.com for product manuals for complete indications, contraindications, warnings, precautions and potential adverse events. Rx only. Rev 0422 TYRX™ Neuro Absorbable Antibacterial Envelope Brief Statement The TYRX™ Neuro Absorbable Antibacterial Envelope is intended to hold a vagus nerve stimulator, a spinal cord neuromodulator, a deep brain stimulator or a sacral nerve stimulator securely in order to create a stable environment when implanted in the body. The Neuro Antibacterial Envelope contains the antimicrobial agents Minocycline and Rifampin which, have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of a pulse generator. The Neuro Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, Rifampin, or absorbable sutures. The Neuro Antibacterial Envelope is also NOT indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). This device is intended to be used in conjunction with vagus nerve stimulators or deep brain stimulators implanted in the infraclavicular fossa, or in conjunction with spinal cord neuromodulators or sacral nerve stimulators implanted laterally to the body midline and slightly superior to the gluteal region. The use of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because Minocycline and Rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the Neuro Antibacterial Envelope and who are also taking methoxyflurane should be monitored carefully for signs of renal toxicity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Last year, ADCES received funding from the Centers for Disease Control and Prevention toward work aimed at advancing access to diabetes education and prevention resources for those in underserved communities. In anticipation of updates on progress made thus far at this year's upcoming annual meeting, we're resharing a previous episode of The Huddle in which Angela Forfia from ADCES and Sarah Ann Piper from Emory Centers explained how this will come to life over the next 5 years. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

On this episode of The Huddle, Miguel Johns, Co-Founder & CEO of mmnt and creator of Milton, discusses how the use of artificial intelligence (AI) can benefit health care professionals across the diabetes space and how this technology is growing and changing. Topics include addressing some of the current opportunities and challenges associated with AI in health care, how AI can provide improved clinical decision support, and where this technology may be headed in the future.Explore danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org)For more information on Miguel or mmnt, visit Milton | Powered by MMNT (getmilton.com) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

The decision on whether to screen yourself or loved ones for Type 1 diabetes risk can be a very personal one. In the last episode of a three-part series, we're joined by Laura Smith PhD, CDCES and Holly O'Donnell, PhD as they discuss the psychosocial factors to consider when talking about T1D screening—including the reasons why a person may or may not want to be screened and how to talk to children and their families about what a potential diagnosis means for them.Learn more about the Autoimmune Screening Study in Kids here: ASK Research Program / Autoimmunity Screening for Kids / Denver, CO (askhealth.org)Learn more about the Environmental Determinants of Diabetes in the Young study here: The Environmental Determinants of Diabetes in the Young (TEDDY) Web Site (usf.edu) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Registration for ADCES24 is now open! Each year, ADCES' annual conference brings together thousands of professionals in the diabetes care space, and this year's event is not one to miss! Conference chair Lisa Hodgson, RD, CDN, CDCES, FADCES joins The Huddle to share all of the exciting sessions and events to look forward to this year in New Orleans.  Learn more and register at ADCES24 (adcesmeeting.org) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Screening for Type 1 diabetes is crucial for earlier detection and management of the disease, but many people don't know that they should be screened or how to access that screening.  In the 2nd episode in our three-part series on T1D screening, University Hospital's Chief of Staff - Office of President & CEO, Franklin Hickey, PhD, RN, NEA, BC, Executive Director of Community and Population Health, Colette Barrow Adams, PhD, MPA, MDiv, and JDRF Patient Navigator, Courtney Harris joined The Huddle to talk about a partnership with JDRF that has allowed more than 1,000 people to be screened for early T1D in the underserved Newark, New Jersey area. They also discuss the importance of meeting people where they are and understanding barriers to access when looking to increase screening rates. Educational grant support for this episode is provided by Sanofi.Learn more about University Hospital here: Hospital Administration - University Hospital (uhnj.org)Lean more about JDRF here: JDRF - Diabetes - Type 1 Diabetes Research, Advocacy, and SupportLearn more about the partnership between University Hospitals and JDRF here: Inclusive Health: Creating Access to Type 1 Diabetes Screening in Underserved Communities (beyondtype1.org) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Chief Scientific and Medical Officer for the American Diabetes Association, Dr. Bob Gabbay, joined The Huddle live at ADCES' 2023 annual meeting in August. He touched on the challenges of addressing diabetes in primary care and the value of a DCES in this area, as well as the importance of active listening, perceived value, and engaging teaching styles when working with people with diabetes. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Advanced practice dietitian Amy Hess Fischl MS, RD, LDN, BC-ADM, CDE joined The Huddle to talk about the various food factors that can impact glucose levels, how to help people with diabetes address and understand the factors that impact them most, and how people with diabetes may adjust their insulin doses based on these various factors.This podcast is being produced in collaboration with JDRF. JDRF works to improve the lives of individuals living with T1D by providing meaningful educational resources for health care professionals and community members. See a full list of factors that can impact glucose levels on Diatribe here: 42 Factors That Affect Blood Glucose?! A Surprising Update (diatribe.org)Learn more about JDRF here: JDRF - Diabetes - Type 1 Diabetes Research, Advocacy, and Support  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast. Learn more about ADCES and the many benefits of membership at adces.org/about-us/membership.

Addressing the inequities that exist in diabetes care relies on each and every one of us in the diabetes space. On this episode of The Huddle, we spoke with Dr. Osagie Ebekozien, Chief Medical Officer at the T1D Exchange and award-winning researcher. Dr. Ebekozien talked about T1D Exchange's Health Equity Advancement Lab (HEAL) and it's work in advancing health equity for underserved populations. He also outlines actionable steps, no matter how big or small, that DCES across the country can take to advance this work in their practices.Please note, this podcast was originally recorded in 2023, and host Sacha Uelmen has since moved on from ADCES to pursue another professional opportunity.Learn more about T1D Exchange here: T1D Exchange Homepage - T1D Exchange and learn more about the Health Equity Advancement Lab specifically here: HEAL - T1D ExchangeStay up to date on diabetes advocacy initiatives here: Diabetes Advocacy (adces.org)Dive deeper into health equity research at the links below:Addressing type 1 diabetes health inequities in the United States: Approaches from the T1D Exchange QI CollaborativeAchieving Equity in Diabetes Research: Borrowing From the Field of Quality Improvement Using a Practical Framework and Improvement ToolsEquitable Post-COVID-19 Care: A Practical Framework to Integrate Health Equity in Diabetes Management Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast. Learn more about ADCES and the many benefits of membership at adces.org/about-us/membership.

Autores: Márcio Krakauer, Gabriela Cavicchioli, Tarcila Campos Para assistir a esse episódio, acesse também https://eventos.diabetes.org.br/event/247/broadcast-rooms/616

Autores: Denise Ludovico, Magda Tiemi Yamamoto, Rebecca Ortiz La Banca Para assistir a esse episódio, acesse também https://eventos.diabetes.org.br/event/247/broadcast-rooms/616

Autores: Maristela Strufaldi, Priscila Pecoli, Claudia Pieper, Para assistir a esse episódio, acesse também https://eventos.diabetes.org.br/event/247/broadcast-rooms/616

Autores: Fernando Valente, Silvia Ramos, Antonio Roberto Doro Para assistir a esse episódio, acesse também: https://eventos.diabetes.org.br/event/247/broadcast-rooms/616

Live at ADCES23, ADCES Immediate Past President Lucille Hughes, DNP, MSN/Ed, CDCES, BC-ADM, FADCES joined The Huddle to introduce ADCES's new strategic plan, and to explain the importance of community involvement and knowing your worth when it comes to diabetes care and education.View ADCES' full 2024-2028 full strategic plan here: adces-strategic-plan.pdf (sitefinity.cloud)Learn more about the plan in this series of blogs: Advance the Expertise of the DCES: A Core Goal of the 2024-28 ADCES Strategic PlanStrategic Plan Goal #1: Improve Access to Diabetes Care and Education: A Strategic Focus for 2024 and Beyond (adces.org)Growing and Diversifying ADCES Membership: A Longstanding Domain in Strategic Priorities Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle/podcast. Learn more about ADCES and the many benefits of membership at adces.org.

Understanding the ins and outs of Type 1 diabetes and its stages is key in accurately screening for and managing the disease. In the first of a three-part series, we're joined by Associate Vice President of T1D Education and Clinical Implementation at JDRF and 2023 Diabetes Educator of the Year Anastasia Albanese-O'Neill, PhD, APRN, CDCES. In this episode, Dr. O'Neill talks about common misconceptions of T1D, as well as the stages of T1D and the importance of evaluating and understanding these stages when diagnosing and working with people and families affected by T1D.  Educational grant support for this episode is provided by Sanofi. Learn more about T1D risk screening and additional resources on JDRF's website: https://www.jdrf.org/t1d-resources/t1detect/ Learn more and gain access to T1D screening kits via TrialNet: https://www.trialnet.org/ or ASK: https://www.askhealth.org/?_ga=2.144097589.1682361371.1702935724-1205645336.1702935724 Learn more about the Search for Diabetes in Youth study here: SEARCH FOR DIABETES IN YOUTH Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle/podcast. Learn more about ADCES and the many benefits of membership at adces.org.

Imagine having type 1 diabetes, taking insulin and not being able to monitor your blood glucose levels at home until that technology was developed and made available to you forty years after your diagnosis. Today's episode is a candid conversation with my best friend's mom, Jeanine, about living with type 1 diabetes for over 65 years. She's seen a lot of changes in diabetes treatment and management during that time – but says that she never felt like she couldn't do something because she had diabetes. This interview was recorded almost exactly six years ago. It has not been released until now. Jeanine recently celebrated her 80th birthday and is doing very well. She adjusted to a new closed loop monitor and pump last year and still enjoys a variety of activities at her senior center – swimming, pickleball, bocce ball, biking, walking, cards and book club. Tune into this episode to learn about Jeanine's story including: ·       diagnosis at 13 years old ·       how the diagnosis impacted her family ·       learning to take different types of insulin ·       playing basketball in high school ·       new language guidance from ADCES ·       hypoglycemia symptoms, treatment, unawareness ·       blood glucose monitoring, CGM ·       pump therapy ·       diet therapy – exchanges, carb counting, reading food labels, sugar free foods ·       how being a home economist taught her skills that helped her manage diabetes ·       swimming and other exercise ·       prenatal care, pregnancy and delivery ·       having a positive attitude and outlook ·       Joslin Medal and research study ·       Peanut M-n-Ms and sweet corn Full shownotes, transcript and resources at: https://soundbitesrd.com/252              

Guests Gwen Klinkner, DNP, RN, BC-ADM, CDCES, FADCES, and Melissa Magwire, RN, MSN, CDCES describe how to help patients with diabetes navigate behavior change principles to achieve glucose management including nutrition and exercise. They also examine pharmacotherapies for weight loss with glucose-lowering medications.CE Link: pcna.net/podcast/euglycemiaSURMOUNT Trials: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 ADCES: https://www.diabeteseducator.org/PNCA.net AHA.org Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: doi: 10.1136/bmj.321.7258.405Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: AHA Scientific Statement: doi:10.1161/CIR.0000000000001040Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the ADA, ADCES, AND, AAFP, AAPA, AANP, APhA: doi:10.1177/0145721720930959See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this podcast, Rena' Thompson, RN, WTA, CDCES, discusses the use of continuous glucose monitors (CGMs) in older adults in home health, including the benefits, challenges, and barriers to using CGMs and the results of a study that gauges clinicians' knowledge of CGMs in a home health setting. She also discussed this topic at ADCES 2023 during a poster presentation titled "Use of Continuous Glucose Monitors in Older Adults in Home Health."

Episode Summary:Angela Forfia from ADCES and Sarah Ann Piper from Emory Centers joined us live at ADCES23 to talk about an exciting new partnership on a grant offered by the Centers for Disease Control and Prevention. The grant will focus on advancing access to diabetes education and prevention resources for those in underserved communities. Hear as Angela and Sarah explain how this will come to life over the next 5 years.Resources:Learn more about the MATCH grant and ADCES's role here: Association of Diabetes Care and Education Specialists to participate in $50 million cooperative agreement to expand diabetes prevention efforts. (diabeteseducator.org)Learn more about Emory Centers here: Home - Emory Centers for Public Health Training and Technical Assistance

In this podcast, Livleen Gill, MBA, RDN, LDN, FAND, discusses creating a standardized care delivery system for older adults with type 2 diabetes in Maryland, connecting health care with community-based organizations, and ways to replicate it nationwide. She also discussed this topic during her poster presentation at ADCES 2023 titled “A model for a scalable technology-enabled evidence-based diabetes care pathway for older adults."

Hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers. Video Version: https://www.hcplive.com/view/diabetes-dialogue-tandem-mobi-and-welldoc-bluestar-platform

In this podcast, Ellen Ospelt, RN, BS, CDCES, discusses the confidence and aptitude people living with insulin-requiring diabetes demonstrate in using CGM alone, including understanding technology, numeracy, and diabetes distress. She also discussed this topic during her poster presentation at ADCES 2023 titled “Is CGM Alone Appropriate for All People with Diabetes on MDI Therapy? Confidence versus Aptitude.”

In this podcast, Eyitayo Owolabi, PhD, RN, discusses how diabetes technology is being used to support and educate patients with newly diagnosed type 2 diabetes, including addressing health care access barriers and promoting medication use, blood glucose monitoring, risk-reduction, problem-solving, healthy, coping, engaging in health dietary practices, and physical activity. Dr Owolabi also presented on this topic at ADCES 2023 during a poster presentation titled Technology-Based Diabetes Education and Support for Persons Newly Diagnosed with T2D: A Scoping Review.

In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th-anniversary celebration. Video version: https://www.hcplive.com/view/diabetes-dialogue-adces-2023-recap

In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023. Video version: https://www.hcplive.com/view/diabetes-dialogue-the-role-of-nutrition-in-diabetes-management-with-dawn-noe-rdn-ld

Erin Akers is back on the pod! Erin is the founder of the Diabulimia Helpline, now DBH. In this episode Rob, Eritrea, and Erin talk about: * Diabulimia Helpline's transition to DBH * Erin's mother and one of the GOATs, Mama Dawn * The 3rd International Conference on Diabetes & Eating Disorders In November * Presenting at ADCES in Houston this year * Broader world of Mental Health and Diabetes including burnout, anxiety, and depression * The importance of group support * Representation matters especially in conversations about disordered eating * The warning signs of diabulimia * The destructive nature of toxic positivity * Want to volunteer for the helpline? Send an email to info@dbh.org We want to hear from you. Send your questions, comments, queries, and general diabetes concerns to THE MAILBAG at mailbag@diabeticsdoingthings.com!

To learn more and register for this year's annual conference, visit adcesmeeting.org.To learn more about ADCES's 50th anniversary and hear stories from our members, visit ADCES 50th Anniversary (diabeteseducator.org)To become a member of ADCES, visit diabeteseducator.org/join

To learn more about diabetes camps and find or support camps near you, visit the Diabetes Education & Camping Association at: Diabetes Education & Camping Association – Uniting the Global Diabetes Camping Community through Education and Leadership (diabetescamps.org)To access training modules provided by the American Diabetes Association, visit: American Diabetes Association | Research, Education, Advocacy

Thomas Blevins, MD, an Endocrinologist from Texas Diabetes and Endocrinology in Austin, TX, joins The Huddle to talk about interchangeable biosimilar insulin. We discuss what interchangeability means and the evidence supporting it. You'll also hear about the options interchangeable biosimilar insulin presents for healthcare systems and people with diabetes.This episode is sponsored by ViatrisResourcesWebinar on Interchangeable Biosimilar Insulin (Free and non-CE):  The New Frontier of Interchangeable Biosimilar Insulins  - bit.ly/3vxUWZ1Tip Sheets on Interchangeable Biosimilar Insulin in English Viatris_Tip_Sheet_v3_04202022 (diabeteseducator.org) and Spanish Viatris_Tip_Sheet_v3_04202022_spa (diabeteseducator.org)Insulin delivery resources from ADCES: www.DiabetesEducator.org/InsulinBlevins, T. C., Barve, A., Raiter, Y., Aubonnet, P., Athalye, S., Sun, B., & Muniz, R. (2020). Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study. Diabetes, obesity & metabolism, 22(3), 365–372. https://doi.org/10.1111/dom.13904Viatris website: http://www.viatris.com

On this episode of The Huddle we talk to Mary Lou Perry, who brings more than 30 years of experience in the area of diabetes nutrition clinical practice and was appointed to the ADA Professional Practice Committee last March. Mary Lou shares how others can be a part of the committee, a few key highlights from the 2023 ADA Standards of Care, and examples of how the updated standards can be applied in practice.Resources:To read the full 2023 Standards of Care, visit: https://diabetesjournals.org/care/issue/46/Supplement_1To watch an ADCES webinar that dives a bit deeper into the Standards of Care, visit: http://send.adces.org/link.cfm?r=5gLLYpGIeV6Y9dpuQo-W2A~~&pe=IajtqA5LETl6XmGrk0YTISnsQijzMKrfWkc79cPqpTRNp3eEShKQUAVzFBrLt-EYJga4sPUlv60Ad-aq--2vbw~~&t=VmwSIkiOmBxB5rwPQvGKrw~~To apply to be a part of an ADA committee, visit: https://diabetes.org/about-us/who-we-are/applications/national-committees-call-applicationsFor ADA public comment, visit: professional.diabetes.org/SOC

    Susan Weiner SPEAKER | AUTHOR MS | RDN | CDCES | FADCES Susan Weiner is an award-winning nutrition, health and diabetes expert and the owner of Susan Weiner Nutrition, PLLC. Susan served as the 2015 ADCES Diabetes Educator of the Year and is an ADCES fellow. Among her many distinguished awards, she is the recipient of the 2019 Metropolitan New York Association of Diabetes Educators Advocate of the Year Award and the 2018 Media Excellence Award from the New York State Academy of Nutrition and Dietetics. Susan is the “Diabetes in Real Life” columnist for Endocrine Today and is the on-air host for video interviews and content for Healio.com. She is the co-author of The Complete Diabetes Organizer: Your Guide to a Less Stressful and More Manageable Diabetes Life and Diabetes: 365 Tips for Living Well. Susan has extensive TV, radio, podcast and video experience and is well versed in media communications. Susan is a well-respected national and international speaker on a variety of topics related to nutrition, diabetes, wellness and health, and has authored dozens of articles in peer reviewed journals. She has authored and been cited in over 300 articles for popular press, consumer publications and online sites. Susan earned her Master's Degree in Applied Physiology and Nutrition from Columbia University. Susan Weiner, MS RDN CDCES FADCES Owner and Clinical Director, Susan Weiner Nutrition PLLC 2015 ADCES Diabetes Educator of the Year Diabetes In Real Life columnist, Endocrine Today New Website! www.susanweinernutrition.com - @susangweiner     The Happy Diabetic Kitchen Podcast is sponsored by US MED Please visit https://www.usmed.com/happydiabetic/ today for a free benefits check   US MED WELCOMES THE HAPPY DIABETIC COMMUNITY When it comes to your health, nothing else matters. That's why with US MED, your health matters to us. From insulin pumps, continuous glucose monitors, blood glucose strips and more, your well-being is in the right hands with the experts at US MED. Call Us : 888-885-0012  

In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.

Allyson Hughes, PhD, is an assistant professor at Ohio University's Diabetes Institute. She's a research psychologist by training but has developed a unique ability to turn data into policy change. You'll hear about her unique perspective as a researcher and person with diabetes and get some direction on how you can leverage your research or findings for real change in the world of policy.Show NotesT1D Exchange https://t1dexchange.org/Quality Improvement Collaboration through T1D Exchange: https://t1dexchange.org/quality-improvement/collaborative/Learn more about the ADCES Annual Conference at www.ADCESmeeting.orgGet involved with ADCES Advocacy and Virtual Hill Day at www.diabeteseducator.org/advocacyLearn more about research at ADCES at www.diabeteseducator.org/researchLearn more about diabetes technology at www.Danatech.org

In this episode, we will be talking with Ms. Melanie Teslik a certified diabetes care and educational specialist. In this episode, we will be discussing lipohypertrophy its causes, tips for management, and myths and misconceptions she addresses as a diabetes nurse educator. Ms. Teslik is a certified diabetes care and education specialist and board certified in advanced diabetes management. She has been an active member of ADCES for over 12 years. Ms. Teslik is a past president of the local chapter and was named Diabetes Educator of the Year in 2016. She has also participated in numerous national committees. She has been working as a Diabetes Nurse Educator for over 12 years at NYU Langone Long Island and has dedicated her life to always being the patient advocate and teacher… “The other thing is people think that, gotta give the injections in a small area. No, you have your whole area up to, you know, the love handles” Question of the Day: Are you taking your insulin at the same injection site? In this episode you will learn: What is Lipohypertrophy? How to identify Lipohypertrophy Methods to prevent Lipohypertrophy How to properly give insulin Connect with Melanie: ADCES Connect with Yumlish: Website Instagram Twitter Facebook LinkedIn --- Send in a voice message: https://anchor.fm/yumlish/message

Christie Schumacher PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, joins The Huddle to talk through the use of GLP-1 and GIP/GLP-1 receptor agonists for your people with type 2 diabetes.  You'll learn what medications fall into the class of GLP-1 and GIP/GLP-1 receptor agonists, how they work and the benefits they can offer people with type 2 diabetes. These medications can be a useful tool in the therapeutic toolkit as highlighted in the recently updated ADA/EASD consensus statement, so this episode will offer practical considerations when initiating GLP-1 and GIP/GLP-1 receptor agonists in patients and managing possible side effects.We want to thank our sponsor, Lilly Diabetes, for their support of this episode.VV-MED-128766 ©2022 Lilly USA, LLC.  All rights reservedResources:ADA and EASD Consensus Report for the Management of Hyperglycemia in Type 2 Diabetes, 2022:  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetes Care | American Diabetes Association (diabetesjournals.org)ADCES Incretin-Based therapies tip sheet: DiabetesEducator.org/docs/default-source/living-with-diabetes/tip-sheets/medication-taking/incretin-based_therapies_tip_sheet_1006202291a90b03-fff9-4b81-98c9-42ef98f0c501.pdfEpisode Transcript: DiabetesEducator.org/docs/default-source/podcast-docs/incretin-full-show.docxMedication Taking Resources from ADCES: 1) For healthcare professionals: DiabetesEducator.org/MedicationTaking 2) For people with diabetes:  DiabetesEducator.org/TakingMedication

The National Practice Survey is conducted once every 5 years to help ADCES understand current trends in the diabetes care and education specialist workforce and how their services are integrated into the full care team. 2022 ADCES President Jan Kavookjian, PhD, MBA, FAPhA, FADCES, joins us to discuss why this survey is so important. She gives us a teaser of some of this year's findings and explains how the results influence strategic planning and key initiatives at the association. ADCES gratefully acknowledges Joanne Rinker, MS, RDN, CDCES, LND, FADCES, Sheryl Traficano and the Certification Board for Diabetes Care and Education, the National Practice Survey writing group and any others involved for their support of the National Practice Survey.ResourcesKavookjian J, Bzowyckyj AS, DiNardo MM, et al. Current and Emerging Trends in Diabetes Care and Education: 2021 National Practice and Workforce Survey. The Science of Diabetes Self-Management and Care. 2022;48(5):307-323. doi:10.1177/26350106221120787ADCES Blog Post: Key Takeaways from Current and Emerging Trends in Diabetes Care & Education: 2021 National Practice and Workforce Survey: www.diabeteseducator.org/news/perspectives/adces-blog-details/adces-perspectives-on-diabetes-care/2022/10/10/key-takeaways-from-current-and-emerging-trends-in-diabetes-care-education-2021-national-practice-and-workforce-surveyValue of the DCES Toolkit: www.DiabetesEducator.org/ValueAsk the Reimbursement Expert: www.diabeteseducator.org/practice/ask-the-expert

Dr Jane Jeffrie Seley, MPH, MSN, NP, RN, APRN, BC-ADM, CDCES, FADCES, brings us the top highlights from the technology seen at the ADCES22 conference in Baltimore this year. She's talking about what's new and what's next in CGM, BGM, insulin delivery, connected devices, and more.  Jane references specific of devices and manufacturers here, but keep in mind that these references are for educational purposes and do not represent an endorsement from ADCES.Show NotesADCES22 sessions on demand: ADCES22.orgLearn more about the latest diabetes technology: Danatech.org 

In this episode of Diabetes Dialogue, which was filmed days after the conclusion of ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the conference, their favorite sessions, and how ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

In this edition of Diabetes Dialogue, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management. During her time at the meeting, Clements was the primary presenter for a trio of sessions focus on U-500 insulin in the inpatient setting, treatment and prevention strategies for hypoglycemia, and clinical implications for SGLT2 inhibitors.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O'Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

In this ADCES 22 special edition episode of Diabetes Dialogue, our hosts are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff pscyhologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward. More information on these sites can be found at DiabetesWise.org and Provider.DiabetesWise.org.

Join us as we welcome Dr. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, an associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy. Dr. Cornell provides insight into ADCES, its benefits, and obtaining credentials as a practicing pharmacist interested in diabetes care. Pharmacists are only a small portion of diabetes educators and obtaining credentialing can provide more opportunities. Listen in to learn about ways you can get involved from an esteemed pharmacist with over 25 years of experience in diabetes management. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us as we welcome Dr. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, an associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy. Dr. Cornell provides insight into ADCES, its benefits, and obtaining credentials as a practicing pharmacist interested in diabetes care. Pharmacists are only a small portion of diabetes educators and obtaining credentialing can provide more opportunities. Listen in to learn about ways you can get involved from an esteemed pharmacist with over 25 years of experience in diabetes management. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us as we welcome Dr. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, an associate director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy. Dr. Cornell provides insight into ADCES, its benefits, and obtaining credentials as a practicing pharmacist interested in diabetes care. Pharmacists are only a small portion of diabetes educators and obtaining credentialing can provide more opportunities. Listen in to learn about ways you can get involved from an esteemed pharmacist with over 25 years of experience in diabetes management. Learn more about your ad choices. Visit megaphone.fm/adchoices

Resources:Galloway, Nicholas, et al. “Exploring the Role of Precision Medicine in Diabetes Diagnoses.” ADCES in Practice, vol. 10, no. 1, Jan. 2022, pp. 26–32, doi:10.1177/2633559X211060849.

Join us for season 2, episode 2 where we give you the run down on diabetes and the vestibular system! Follow us on instagram @adoseofdizzypodcast References: Piker, E. G., & Romero, D. J. (2019, November). Diabetes and the vestibular system. In Seminars in hearing (Vol. 40, No. 04, pp. 300-307). Thieme Medical Publishers. Piker, E. G., Spankovich, C., Romero, D. J., Memering, C. E., & Pierantoni, J. A. (2020). What You Need to Know About the Hearing and Vestibular Consequences of Diabetes. ADCES in Practice, 8(5), 20-27. Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012). Type 2 diabetes mellitus: a review of current trends. Oman medical journal, 27(4), 269–273.

ResourcesResources for Spanish-speaking people with diabetes: DiabetesEducator.org/Spanish.Live and recorded ADCES webinars: DiabetesEducator.org/webinars.Tools and resources for people with diabetes: DiabetesDducator.org/living-with-diabetes/Tools-and-ResourcesADCES Diabetes Education and Care Curriculum (book).ADCES Quick Guide to Medications, 11th Edition (book).The Art and Science of Diabetes Care and Education. 5th edition, also known as the desk reference (book).Learn more about National Diabetes Education Week at DiabetesEducator.org/NDEW.

The goal of diabetes care is not to lose weight! - Megrette Fletcher M.Ed., RDN, CDCES .  Megrette joins the podcast today to discuss the problem with diet culture and weight stigma in diabetes care, and why focusing on weight can sabotage diabetes care. About Megrette:Megrette Fletcher is a registered dietitian, diabetes care and education specialist, public speaker, and author. She is a member of the Association of Diabetes Care and Education Specialists and served on the ADCES inclusion committee national conference from 2018-2020. Megrette is a mindful eating leader and co-founder of The Center for Mindful Eating. She is a co-founder of WN4DCSymposium.com and the current owner. She is the creator of the NoWeightLossRequired.com community for weight-inclusive diabetes care. Her focus, on decreasing stigma in diabetes care, fuels her passion for weight-neutral diabetes care, treatment, and prevention. To learn more about weight inclusive diabetes visit the website at wn4dc.com. What you'll learn by listening:Megrette shares her passion for changing the landscape in diabetes care, and how diet culture in diabetes has challenged her values of non judgement and self-compassionWhy focusing on weight can sabotage diabetes careHow one can begin establishing a sustainable diabetes strategy free of diet culture influencesWhat to do when a medical appointment feels icky because of weight biasMegrette busts a common myth in diabetesMegrette's new diet free resource for people living with diabetesHow to connect with Megrette:Instagram: https://www.instagram.com/noweightlossrequired/Facebook: https://www.facebook.com/noweightlossrequired/Website: https://www.wn4dc.comProgram/Resources Mentioned by Megrette:NoWeightlossRequired.com 7 day introduction program https://www.noweightlossrequired.comLink for No weight loss required membership programhttps://wn4dc.com/private_pages/4520409?preview=logged_out$1 Link to the Ready to Being programhttps://no-weight-loss-required.circle.so/checkout/pro-access-rtbLink to 12 week email with $1 VIP access direct link with the $1 VIP access  How to connect with Lindsay:Show idea/question? Email: lindsay@lindsaysarson.comInstagram: https://instagram.com/theintuitivediabetic/Free Food Freedom Roadmap: https://www.lindsaysarson.comWork with me: https://www.lindsaysarson.com/work-with-me 

Resources:Share the barriers you identified and how you resolved them through the ADCES Technology Community of Interest:  www.adcesconnect.org/technology-coiMacLeod, J., Scher, L., Greenwood, D., Isaacs, D., Albanese-O'Neill, A., O'Neill, M. S., Golden, L., & Scalzo, P. (2021). Technology Disparities and Therapeutic Inertia: A Call to Action for the Diabetes Care and Education Specialist. ADCES in Practice, 9(5), 34–41. https://doi.org/10.1177/2633559X211032227Utilizing A Technology Framework to Reduce Disparities and Therapeutic Inertia, from the ADCES blog:  https://www.diabeteseducator.org/news/perspectives/aade-blog-details/adces-perspectives-on-diabetes-care/2021/09/28/utilizing-a-technology-framework-to-reduce-disparities-and-therapeutic-inertia.Thank you to the practice paper authors Janice MacLeod, MA, RD, CDCES, FADCES, LaurieAnn Scher, MS, RD, CDCES, Deborah Greenwood, PhD, RN, BC-ADM, CDCES, FADCES, Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, Anastasia Albanese-O'Neill, PhD, APRN, CDCES, Megan S. O'Neill, PA-C, CDCES, Lisa Golden, MA, ED, HD, CRC, CDCES, and Patty Scalzo, MSN, NP, RN, CDCES.

Learn more about integrating technology into your practice at DiabetesEducator.org/TechnologyIntegration. Find all things diabetes tech at danatech.org, an ADCES member-only benefit. 

Resources Mobley-Bukstein, W., Reece, S. (Mandy), & Hebdon, K. (2021). Special Considerations in the Management and Education of Older Persons With Diabetes. ADCES in Practice, 9(4), 30–42. https://doi.org/10.1177/2633559X211015972ADCES21 Education session: S25 - Medications, Technology and Behavior Change for Older Adults With Diabetes. Saturday, August 14, 2021.Register at ADCES21.org to attend. 

ResourcesIsis Evans, E., Hong, J., Mattison, M., & Capoccia, K. (2020). Cannabidiol: Navigating the Evidence. ADCES in Practice, 8(5), 42–51. https://doi.org/10.1177/2633559X20943159Register at ADCES21.org to attend Kam's presentation: S05 - Medical Marijuana and CBD Use in Diabetes.

ResourcesTo access the paper discussed in today's episode Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps visit https://rdcu.be/cbnLl. Check out the ADCES blog for more tips from this paper. htps://www.diabeteseducator.org/news/perspectives/aade-blog-details/adces-perspectives-on-diabetes-care/2021/02/09/caring-for-hospitalized-patients-with-diabetes-hyperglycemia-and-covid-19-bridging-the-remaining-knowledge-gapsFor additional guidance and resources on COVID-19 and diabetes care, visit DiabetesEducator.org/COVID-19. For vaccine information, visit DiabetesEducator.org/COVID-19vaccine. Additional study: How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit:  https://journals.sagepub.com/doi/pdf/10.1177/1932296820978399 

Resources:Subscribe to the Advocacy Forum for real-time updates at DiabetesEducator.org/Advocacy.Access the legislation action center at DiabetesEducator.org/ActNow.

Danatech is the one-stop shop for diabetes technology. ADCES members can access danatech for free at www.Danatech.org.

Resources: ADCES guidance on technology is now available in two practice papers available  at DiabetesEducator.org/TechnologyIntegration.Danatech was developed to support the technology access and assessment needs of healthcare professionals who care for patients living with diabetes and other chronic conditions. Danatech is free to ADCES members, log in in today Danatech.org.ADCES workforce training offers customized training on topics like CGM, insulin pump therapy and pattern management. Learn more about this training at DiabetesEducator.org/Workforce. ReferenceIsaacs, D., Cox, C., Schwab, K., Oser, T. K., Rinker, J., Mason, M. J., … Albanese-O'Neill, A. (2020). Technology Integration: The Role of the Diabetes Care and Education Specialist in Practice. The Diabetes Educator, 46(4), 323–334. https://doi.org/10.1177/0145721720935123 

ResourcesADCES guidance on technology is now available in two practice papers available  at DiabetesEducator.org/TechnologyIntegration.Danatech was developed to support the technology access and assessment needs of healthcare professionals who care for patients living with diabetes and other chronic conditions. Danatech is free to ADCES members, log in in today danatech.org.ADCES workforce training offers customized training on topics like CGM, insulin pump therapy and pattern management. Learn more about this training at DiabetesEducator.org/Workforce. Reference Greenwood, D. A., Howell, F., Scher, L., Yousef, G., Rinker, J., Yehl, K., … Peeples, M. M. (2020). A Framework for Optimizing Technology-Enabled Diabetes and Cardiometabolic Care and Education: The Role of the Diabetes Care and Education Specialist. The Diabetes Educator, 46(4), 315–322. https://doi.org/10.1177/0145721720935125 

To access the competencies for diabetes care and education specialists or to download the self-assessment worksheets, visit DiabetesEducator.org/DCEScompetencies. Reference:Ryan, D., Burke, S. D., Litchman, M. L., Bronich-Hall, L., Kolb, L., Rinker, J., & Yehl, K. (2020). Competencies for Diabetes Care and Education Specialists. The Diabetes Educator, 46(4), 384–397. https://doi.org/10.1177/0145721720931092